Speaker Programs and Manufacturer Remuneration for Off-Label Promotion

Speaker Programs and Manufacturer Remuneration for Off-Label Promotion at a Glance

Speaker programs, in which manufacturers compensate physicians to promote their products, raise significant legal concerns under the Anti-Kickback Statute (AKS). These programs are often scrutinized for potential violations, particularly when tied to off-label promotion or when remuneration is intended to induce prescriptions. The Department of Justice and the Office of Inspector General (OIG) have issued guidance and enforcement actions highlighting the risks associated with such programs, particularly when they involve excessive compensation, lack of clinical relevance, or are controlled by sales teams.

The Legal Framework

The Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), prohibits the offer, payment, solicitation, or receipt of remuneration to induce or reward referrals of items or services payable by a federal health care program. This prohibition applies broadly and is not limited to specific types of payments or services. The statute carries criminal penalties, including fines of up to $100,000 or imprisonment of up to 10 years, or both, for knowing and willful violations.

Safe harbor regulations, found at 42 C.F.R. § 1001.952, provide exceptions to the AKS in certain circumstances. These exceptions include, but are not limited to, investment interests, space rental, equipment rental, personal services and management contracts, referral services, group purchasing organizations, and electronic health records items and services. However, speaker programs are not explicitly covered by any of these safe harbors, and they are instead analyzed under the general provisions of the AKS and the one-purpose test.

Enforcement and Cases

The Third Circuit in United States v. Greber, 760 F.2d 68 (3d Cir. 1985) established that the AKS is violated if payments are intended to induce a physician to use the payor's services, even if the payments are also intended to compensate for legitimate professional services. This "one-purpose test" is a key factor in evaluating whether remuneration crosses the line into illegal kickbacks. In 2022, Biogen Inc. agreed to pay $900 million to resolve allegations that it had violated the AKS by compensating physicians through speaker honoraria, training fees, and meals to induce prescriptions of its drugs. Additionally, the HHS OIG issued a Special Fraud Alert in 2020 highlighting the risks of speaker programs, including characteristics such as excessive meals, alcohol, and compensation tied to business volume.

The Federal Overlay

The federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), makes it a felony to knowingly and willfully offer, pay, solicit, or receive remuneration to induce or reward referrals of items or services payable by a federal health care program. The Stark Law, 42 U.S.C. § 1395nn, separately prohibits physician self-referrals for designated health services payable by Medicare or Medicaid, on strict-liability terms. Both regimes carry safe harbors and exceptions published at 42 C.F.R. § 1001.952. State referral and fee-splitting statutes operate alongside these federal prohibitions and can apply even where no federal program payment is involved.

Reading the Research Desk

For further information, see our related research pages: Practice Areas, The Anti-Kickback Statute Explained, Safe Harbors Under the Anti-Kickback Statute, AKS and Stark Law Overlap, Recent Anti-Kickback Statute Decisions, and FAQ.